POLR3H: A Potential Drug Target and Biomarker (G171568)

Target Name: POLR3H

NCBI ID: G171568

POLR3H

POLR3H: A Potential Drug Target and Biomarker

Purine nucleoside processing RNA polymerase (POLR3H) is a key enzyme in the DNA replication process of eukaryotic cells. It plays a crucial role in the production of new DNA copies, which are used for cell growth, repair, and transcription. PolR3H is the enzyme responsible for the initial step of the polymerase reaction, which involves the formation of a single-stranded RNA template that will be used to synthesize a new DNA strand.

The research on POLR3H has led to the identification of several potential drug targets. One of the main targets is the inhibition of polR3H has been shown to be effective in treating various diseases, including cancer, HIV, and genetic disorders. In addition, the over-expression of polR3H has also been shown to be associated with the development of certain diseases, such as neurodegenerative diseases and autoimmune diseases.

Another potential drug target for POLR3H is the inhibition of its function. Many drugs used in the treatment of cancer and other diseases work by inhibiting the activity of polR3H. For example, the drug tamoxifen is commonly used to treat breast cancer, and it works by inhibiting the activity of polR3H in breast tissue.

In addition to its potential as a drug target, POLR3H has also been identified as a potential biomarker. The expression of polR3H has been shown to be affected by various factors, including temperature, pH, and nucleotide availability. Therefore, the levels of polR3H expression can be used as a marker for certain diseases and conditions.

One of the main applications of polR3H as a biomarker is its potential use in disease diagnosis. For example, the levels of polR3H expression have been shown to be elevated in certain types of cancer, which could be used as a diagnostic marker for these diseases. Additionally, the levels of polR3H expression have also been used as a marker for other conditions, such as infection and inflammation.

Another potential application of polR3H as a biomarker is its use in drug development. Many drugs used in the treatment of cancer and other diseases work by inhibiting the activity of polR3H. Therefore, the levels of polR3H expression can be used as a marker for the development and evaluation of new drugs.

In conclusion, the research on POLR3H has led to the identification of several potential drug targets and biomarkers. The inhibition of polR3H has been shown to be effective in treating various diseases, including cancer, HIV, and genetic disorders. Additionally, the over-expression of polR3H has also been shown to be associated with the development of certain diseases. Therefore, the levels of polR3H expression can be used as a marker for certain diseases and conditions, as well as a potential drug target and biomarker.

Protein Name: RNA Polymerase III Subunit H

Functions: DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Specific peripheric component of RNA polymerase III which synthesizes small RNAs, such as 5S rRNA and tRNAs. Plays a key role in sensing and limiting infection by intracellular bacteria and DNA viruses. Acts as nuclear and cytosolic DNA sensor involved in innate immune response. Can sense non-self dsDNA that serves as template for transcription into dsRNA. The non-self RNA polymerase III transcripts, such as Epstein-Barr virus-encoded RNAs (EBERs) induce type I interferon and NF- Kappa-B through the RIG-I pathway (By similarity)

The "POLR3H Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLR3H comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets